

UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/674,752	Johannes Jacobus Voorberg	294-86

INTERNATIONAL APPLICATION NO.

PCT/NL99/00285

LA. FILING DATE	PRIORITY DATE
-----------------	---------------

05/07/1999

05/08/1998

Ronald J Baron
 Hoffmann & Baron
 6900 Jericho Turnpike
 Syosset, NY 11791

CONFIRMATION NO. 5298

371 FORMALITIES LETTER



OC000000008850848

Date Mailed: 09/25/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Information Disclosure Statements
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Request for Immediate Examination

Applicant's response filed 12/29/2000 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 12/01/2000 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)


*A copy of this notice **MUST** be returned with the response.*

PAULETTE R KIDWELL

Telephone: (703) 305-3656

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/674,752	PCT/NL99/00285	294-86



DTOS Rec'd PCT/PTO

29 OCT 2002

Attorney Docket No. 294-86 PCT/US

In re Application of: Voorberg, et al.

Serial No.: 09/674,752

Confirmation No.: 5298

Filed: December 29, 2000

For: METHOD FOR DIAGNOSIS AND
TREATMENT OF HEMOPHILIA A
PATIENTS WITH AN INHIBITORCOMMISSIONER FOR PATENTS
Washington, DC 20231

I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
U.S. Patent and Trademark Office, Box Sequence, P.O.
Box 2327, Arlington, VA 22202

20231 on October 25, 2002Dated: 10/25/02

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- ☐ Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- ☒ No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 601	MINUS	** 23	= 37
INDEP.	* 8	MINUS	*** 4	= 4

SMALL ENTITY

RATE	ADDL. FEE
x 9=	\$
x 40=	\$
x 135=	\$
TOTAL	\$ 0.00

OR

OTHER THAN A
SMALL ENTITY

RATE	ADDL. FEE
x 18=	\$684.00
x 80=	\$320.00
x 270=	\$
TOTAL	\$ 0.00

OR

☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS

- ☐ Please charge my Deposit Account No. 08-2461 in the amount of \$_____. A duplicate copy of this sheet is attached.
- ☐ A check in the amount of \$_____ is attached.
- ☒ The Commissioner is hereby authorized to charge any fees or additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2461. A duplicate copy of this sheet is attached.
- ☒ Any filing fees under 37 C.F.R. 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. 1.17.

Respectfully submitted,

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, NY 11791
(516) 822-3550
EIG:jlw

Edna I. Gergel, Ph.D.
Registration No. 50,819